1022 related articles for article (PubMed ID: 27537577)
1. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy.
Tai H; Wang MY; Zhao YP; Li LB; Dong QY; Liu XG; Kuang JS
Medicine (Baltimore); 2016 Aug; 95(33):e4541. PubMed ID: 27537577
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Pratley RE; Kipnes MS; Fleck PR; Wilson C; Mekki Q;
Diabetes Obes Metab; 2009 Feb; 11(2):167-76. PubMed ID: 19125778
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.
Pratley RE; Fleck P; Wilson C
Diabetes Obes Metab; 2014 Jul; 16(7):613-21. PubMed ID: 24400655
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
[TBL] [Abstract][Full Text] [Related]
6. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Del Prato S; Camisasca R; Wilson C; Fleck P
Diabetes Obes Metab; 2014 Dec; 16(12):1239-46. PubMed ID: 25132212
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Nauck MA; Ellis GC; Fleck PR; Wilson CA; Mekki Q;
Int J Clin Pract; 2009 Jan; 63(1):46-55. PubMed ID: 19125992
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial.
Ji L; Li L; Kuang J; Yang T; Kim DJ; Kadir AA; Huang CN; Lee D
Diabetes Obes Metab; 2017 May; 19(5):754-758. PubMed ID: 28075066
[TBL] [Abstract][Full Text] [Related]
9. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
[TBL] [Abstract][Full Text] [Related]
12. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
Pratley RE; McCall T; Fleck PR; Wilson CA; Mekki Q
J Am Geriatr Soc; 2009 Nov; 57(11):2011-9. PubMed ID: 19793357
[TBL] [Abstract][Full Text] [Related]
13. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
[TBL] [Abstract][Full Text] [Related]
14. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Rosenstock J; Wilson C; Fleck P
Diabetes Obes Metab; 2013 Oct; 15(10):906-14. PubMed ID: 23531118
[TBL] [Abstract][Full Text] [Related]
15. Xinfeng capsule improves pulmonary function in ankylosing spondylitis patients via NF-ΚB-iNOS-NO signaling pathway.
Liu J; Qi Y; Zheng L; Cao Y; Wan L; Ye W; Fang L
J Tradit Chin Med; 2014 Dec; 34(6):657-65. PubMed ID: 25618969
[TBL] [Abstract][Full Text] [Related]
16. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Bosi E; Ellis GC; Wilson CA; Fleck PR
Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
Curr Med Res Opin; 2011 Sep; 27(9):1781-92. PubMed ID: 21806314
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase.
Kaku K; Mori M; Kanoo T; Katou M; Seino Y
Expert Opin Pharmacother; 2014 Oct; 15(15):2121-30. PubMed ID: 25190226
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
Kim HJ; Jeong IK; Hur KY; Kim SK; Noh JH; Chun SW; Kang ES; Rhee EJ; Choi SH
Diabetes Metab J; 2022 Sep; 46(5):689-700. PubMed ID: 35295073
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study.
Kim JM; Kim SS; Kim JH; Kim MK; Kim TN; Lee SH; Lee CW; Park JY; Kim ES; Lee KJ; Choi YS; Kim DK; Kim IJ
Diabetes Metab J; 2020 Feb; 44(1):67-77. PubMed ID: 31339011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]